Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aslan Pharmaceuticals Ltd (ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ASLN
Nasdaq
8731
http://aslanpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aslan Pharmaceuticals Ltd (ADR
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
- Apr 24th, 2024 11:00 am
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
- Apr 22nd, 2024 12:45 pm
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
- Apr 19th, 2024 9:10 pm
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Apr 12th, 2024 12:00 pm
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
- Apr 9th, 2024 1:40 pm
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
- Mar 27th, 2024 12:07 pm
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
- Mar 20th, 2024 1:40 pm
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
- Mar 12th, 2024 6:34 pm
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
- Mar 12th, 2024 1:58 pm
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
- Mar 11th, 2024 11:00 am
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
- Mar 6th, 2024 12:00 pm
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
- Feb 29th, 2024 12:00 pm
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- Jan 8th, 2024 11:45 am
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
- Jan 2nd, 2024 12:00 pm
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
- Dec 12th, 2023 12:00 pm
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
- Nov 20th, 2023 12:00 pm
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
- Nov 3rd, 2023 11:00 am
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Oct 27th, 2023 12:00 pm
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
- Oct 24th, 2023 12:00 pm
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
- Oct 18th, 2023 11:00 am
Scroll